Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
January 23, 2025 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2025 List of America's Most Successful Mid-Cap Companies

CORAL GABLES, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most...
January 21, 2025 08:19 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Launched FIRDAPSE® in Japan

CORAL GABLES, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
January 08, 2025 12:30 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

CORAL GABLES, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
December 16, 2024 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CORAL GABLES, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
November 25, 2024 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List

CORAL GABLES, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), today announced it ranked number 452 on the Deloitte Technology Fast...
November 19, 2024 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences

CORAL GABLES, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
November 13, 2024 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work

CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
November 06, 2024 16:12 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update

Reports Q3 2024 Total Revenues of $128.7 Million, Representing a 25.3% YoY Increase Record Revenues Driven by Continued Organic Growth in its Rare Disease Franchise Robust Financial Performance...
October 22, 2024 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024

CORAL GABLES, Fla., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...